Eisenmenger's Syndrome in Adults With CHD
This trial is active, not recruiting.
|Sponsor||Children's Healthcare of Atlanta|
|Start date||January 1996|
|Trial size||70 participants|
|Trial identifier||NCT00266903, 05-118|
Review the outcome of treatment with endothelin receptor antagonists (bosentan or sitaxsetan) alone or in combination with Sildenafil (a PDE-5 inhibitor) in adult patients with pulmonary hypertension due to congenital heart disease.
Male or female participants at least 18 years old.
Inclusion Criteria: - Congenital heart disease (unoperated, palliated or repaired) Eisenmenger's syndrome Age 18 to 80 Exclusion Criteria: - Those who do not meet inclusion criteria
|Official title||Treatment of Eisenmenger's Syndrome in Adults With Congenital Heart Disease With Pulmonary Arterial Vasodilators|
|Principal investigator||Wendy M. Book, MD|
|Description||The primary objective of this study is to examine medical records of patients with Eisenmenger's Syndrome in order to determine the effect of endothelin receptor antagonists, alone or in combination, with Sildenafil, on symptoms of pulmonary hypertension. This review will be conducted on Standard of Care procedures such as New York Heart Association (NYHA) classification, six-minute walk exercise capacity, pulmonary pressures and oxygens saturations. Pulmonary pressures determined by echo or cardiac catheterization will be analyzed where available. We hypothesize that patients with congenital heart defects who develop ES will have an improved six-minute walk distance, improved pulmonary arterial pressures and improved oxygenation after treatment with endothelin receptor antagonists and other pulmonary vasodilators.|
Call for more information